Fenofibrate: A Game-changer for Diabetic Retinopathy

Diabetic retinopathy (DR) affects 34.6% of diabetes patients, with 6.8% experiencing diabetic macular edema (DME). Fenofibrate, a lipid-lowering agent, exhibits antioxidative, anti-inflammatory, and antiangiogenic properties that slow DR progression. Clinical trials (Fenofibrate Intervention and Event Lowering in Diabetes, Action to Control Cardiovascular Risk in Diabetes, Lowering Events in Non-proliferative retinopathy in Scotland) demonstrated its efficacy in reducing microvascular complications and the need for laser treatment. Fenofibrate modulates inflammatory pathways, improves endothelial function, and decreases retinal hyperpermeability. While its effects on DME remain inconclusive, it significantly reduces DR progression. As an adjunct therapy, fenofibrate holds promise for improving DR management, making its inclusion in treatment regimens a potential game-changer for diabetes-related eye complications.